Welin L, Elvelin L, Niklasson A, Olsson G, Elmfeldt D
Clinical R&D, Astra Hassle AB, Molndal, Sweden.
Am J Cardiol. 1997 Apr 1;79(7):996-9. doi: 10.1016/s0002-9149(97)00034-9.
All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis. The major finding was that felodipine does not increase mortality or the incidence of major cardiovascular events and that the data indicate a favorable effect.
